TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

7 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Obesity / overweightHigh cholesterol

    Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

    Testing whether daily milk polar lipids affect heart and metabolic risk in adults with belly fat and

    📍 University of Connecticut · Storrs, CT · Get directions →

    The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.

    ✓ Study care freeEarly Phase 1Ages 18–70Learn more →
  • Multiple sclerosis (MS)

    Entire-body PET Scans for Multiple Sclerosis

    Testing whether whole-body PET scans can better track MS brain and nerve damage

    📍 Brain Health Alliance · Ladera Ranch, CA · Get directions →

    To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.

    ✓ Study care freeEarly Phase 1Ages 25–55Learn more →
  • Migraine / chronic headache

    Mechanistic Studies of Psilocybin in Headache Disorders

    Testing how psilocybin may affect migraine headache symptoms

    📍 VA Connecticut Healthcare System · West Haven, CT · Get directions →

    In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect.

    ✓ Study care freeEarly Phase 1Ages 21–70Learn more →
  • Multiple sclerosis (MS)

    Effects of Ublituximab on Motor Functions in Multiple Sclerosis

    Testing whether ublituximab changes walking and fall risk in people with relapsing multiple

    📍 Georgia State University · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment.

    ✓ Study care freeEarly Phase 1Ages 18–55Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh cholesterol

    Akkermansia Muciniphilia and Metabolic Side Effects of ADT

    Testing how Akkermansia gut bacteria relate to body and blood lipid changes in people with obesity

    📍 London Health Sciences Centre - Victoria Hospital · London, Ontario · Get directions →

    The overriding objectives of this study are: 1. Primary outcomes: 1.

    ✓ Study care freeEarly Phase 1Ages 18+MenLearn more →
  • Migraine / chronic headache

    Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?

    Testing whether a nerve block plus steroid tablets lowers migraine headache return within 72 hours

    📍 University Medical Center of El Paso · El Paso, TX · Get directions →

    For some patients who come to the emergency department for treatment of a migraine headache, peripheral headache nerve blocks (PHNB) have proven to be an efficient and effective treatment for headache relief. Previous studies have demonstrated that adding steroids as an adjunct treatment to standard migraine treatment can reduce recurrence of headaches in the subsequent few days.

    ✓ Study care freeEarly Phase 1Ages 18–85Learn more →
  • Multiple sclerosis (MS)

    Assessment of Synaptic Density in MS

    Testing brain imaging to measure synapse density in progressive MS

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    The investigators propose to use the novel SV2a-PET ligand, \[F-18\]SDM-8 to assess synaptic density in progressive multiple sclerosis (PMS) (including primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS)), given its improved imaging characteristics and potential for large scale applicability. The specific aims of the study are: Aim 1: To compare the cortical and subcortical grey matter synaptic density in PMS patients, patients with relapsing-remitting MS (RRMS), and healthy subjects, using a novel \[F-18\] labeled synaptic density PET ligand, \[F-18\]SDM8, also known as \[F-18\]SynvesT-1.

    ✓ Study care freeEarly Phase 1Ages 18–60Learn more →